title: Noninvasive tracer techniques to characterize angiogenesis.
abstract: Great efforts are being made to develop antiangiogenesis drugs for treatment of cancer as well as other diseases. Some of the compounds are already in clinical trials. Imaging techniques allowing noninvasive monitoring of corresponding molecular processes can provide helpful information for planning and controlling corresponding therapeutic approaches but will also be of interest for basic science. Current nuclear medicine techniques focus on the development of tracer targeting the vascular endothelial growth factor (VEGF) system, matrix metalloproteinases (MMP), the ED-B domain of a fibronectin isoform, and the integrin alphavbeta3. In this chapter, the recent tracer developments as well as the preclinical and the clinical evaluations are summarized and the potential of the different approaches to characterize angiogenesis are discussed.
authors.affiliation: Universitätsklinik für Nuklearmedizin, Medizinische Universität Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria. roland.haubner@i-med.ac.at
authors.forename: Roland
authors.initials: R
authors.lastname: Haubner
mesh_terms: D020533:Angiogenesis Inhibitors / Q000494:pharmacology; D000818:Animals; D005353:Fibronectins / Q000276:immunology; D006801:Humans; D007128:Immunoglobulin Fragments / Q000378:metabolism; D039302:Integrin alphaVbeta3 / Q000037:antagonists & inhibitors / Q000378:metabolism; D061965:Matrix Metalloproteinase Inhibitors; D020782:Matrix Metalloproteinases / Q000378:metabolism; D025202:Molecular Diagnostic Techniques; D015335:Molecular Probes / Q000378:metabolism*; D009389:Neovascularization, Pathologic / Q000378:metabolism* / Q000473:pathology / Q000517:prevention & control; D018919:Neovascularization, Physiologic / Q000187:drug effects; D011480:Protease Inhibitors / Q000494:pharmacology; D019275:Radiopharmaceuticals / Q000378:metabolism; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors / Q000378:metabolism; D013194:Staining and Labeling / Q000379:methods; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors / Q000378:metabolism
chemical_list: D020533:Angiogenesis Inhibitors; D005353:Fibronectins; D007128:Immunoglobulin Fragments; D039302:Integrin alphaVbeta3; D061965:Matrix Metalloproteinase Inhibitors; D015335:Molecular Probes; D011480:Protease Inhibitors; D019275:Radiopharmaceuticals; D042461:Vascular Endothelial Growth Factor A; D040262:Receptors, Vascular Endothelial Growth Factor; D020782:Matrix Metalloproteinases